These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 13418464)

  • 21. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
    Brogan GX; Peterson ED; Mulgund J; Bhatt DL; Ohman EM; Gibler WB; Pollack CV; Farkouh ME; Roe MT
    Diabetes Care; 2006 Jan; 29(1):9-14. PubMed ID: 16373888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six hour ambulation after elective coronary angioplasty and stenting with 7F guiding catheters ald low dose heparin.
    Tengiz I; Ercan E; Bozdemir H; Durmaz O; Gurgun C; Nalbantgil I
    Kardiol Pol; 2003 Feb; 58(2):93-7. PubMed ID: 14504634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype.
    Ray KK; Francis S; Crossman DC
    J Thromb Haemost; 2005 Feb; 3(2):287-91. PubMed ID: 15670034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations.
    Levine GN; Ferguson JJ
    Catheter Cardiovasc Interv; 2003 Oct; 60(2):185-93. PubMed ID: 14517923
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of ST-elevation acute coronary syndrome with the aim of reperfusion].
    ;
    Orv Hetil; 2005 Oct; 146(44):2271-2. PubMed ID: 16416564
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of evidence-based management for acute coronary syndrome.
    Tang E; Wong CK; Wilkins G; Herbison P; Williams M; Kay P; Restieaux N
    N Z Med J; 2005 Oct; 118(1223):U1678. PubMed ID: 16224502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
    Wolak A; Ayzenberg Y; Cafri C; Gilutz H; Ilia R; Zahger D
    Int J Cardiol; 2004 Aug; 96(2):151-5. PubMed ID: 15262028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of coronary diseases; treatment of coronary atherosclerosis & its complications].
    CLOAREC M
    Bull Med; 1957; 71(7):221 passim. PubMed ID: 13460557
    [No Abstract]   [Full Text] [Related]  

  • 29. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
    Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of heparin in cases of coronary insufficency; evaluation by electrocardiographic tests.
    RUSSEK HI; URBACH KF; DOERNER AA
    Trans Am Coll Cardiol; 1952; 2():129-33. PubMed ID: 13049503
    [No Abstract]   [Full Text] [Related]  

  • 31. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation.
    Mehran R; Nikolsky E; Camenzind E; Zelizko M; Kranjec I; Seabra-Gomes R; Negoita M; Slack S; Lotan C
    Am Heart J; 2005 Dec; 150(6):1171-6. PubMed ID: 16338254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronary artery stent thrombosis associated with heparin-induced thrombocytopenia: case report and review of the literature.
    Gallagher MJ; Ajluni SC; Almany SL
    J Interv Cardiol; 2005 Apr; 18(2):131-7. PubMed ID: 15882161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experience with the use of heparin in ambular prevention of coronary thrombosis under ambulatory conditions].
    Aleĭnikova LI
    Kardiologiia; 1965; 5(4):50-2. PubMed ID: 5880731
    [No Abstract]   [Full Text] [Related]  

  • 35. Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit.
    Steg PG; Juliard JM
    Eur Heart J; 2004 Oct; 25(19):1667-9. PubMed ID: 15451141
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comments on the treatment of coronary diseases by the synergistic action of a new drug combination].
    DICKER S
    Praxis; 1954 Jun; 43(23):498-500. PubMed ID: 13185934
    [No Abstract]   [Full Text] [Related]  

  • 37. [Coronary disease (except myocardial infarct): clinical, anatomopathological and physiopathologic definition].
    Cah Med; 1970 Dec; 11(16):1323-6. PubMed ID: 5503609
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy of coronary diseases].
    Kübler W
    Med Welt; 1977 Apr; 28(14):663-8. PubMed ID: 853933
    [No Abstract]   [Full Text] [Related]  

  • 39. Heparin in the treatment of macular lesions.
    ROME S
    Trans Pac Coast Otoophthalmol Soc Annu Meet; 1958; 39():203-25; discussion 226-9. PubMed ID: 13635797
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of coronary disease].
    TETREAULT A
    Union Med Can; 1953 Dec; 82(12):1396-9. PubMed ID: 13136605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.